ND-12 Combined With H-6 for Adult Chronic Inflammatory Diarrhea
Early Phase 1 · Testing mesalazine, ND-12 and ND-12/H-6 · 1 site · The Second Hospital of Nanjing Medical University
Official record & contacts on ClinicalTrials.gov ↗
In plain English
What this trial is testing
This study is testing mesalazine (a drug), ND-12 (a drug) and ND-12/H-6 (a drug) as a possible treatment. Condition(s) listed: Diarrhea Chronic and UC - Ulcerative Colitis.
Participants are assigned to groups by chance (randomized).
It is blinded: participants and the study team do not know who receives what.
Early Phase 1 studies are very small first studies in people, mainly checking safety and how the body handles a treatment.
Who can join
- Ages 18 to 75
- Any sex
Some of the main requirements, copied from the record:
- Subjects aged 18-75 years (inclusive), of any gender.
- Meet any one of the following conditions:
- 1) Previously diagnosed ulcerative colitis, currently in the active phase; 2) Diagnosis of chronic diarrhoea: stool frequency ≥3 times per day or markedly higher than the subject's usual baseline; disease duration >4 weeks; recurrent…
Plus 1 more requirement(s). There are also 21 reasons someone might not be able to join (exclusion criteria). Only the trial team can confirm whether you qualify.
What's involved
- About 36 participants are expected to take part.
- Start date: 2026-07-20.
- Main results expected around 2028-08-31 (estimate from the record).
- 1 study site listed (1 marked recruiting) in China.
Main thing being measured
- Fecal calprotectin of patients 14 days after treatment compared to the baseline level (baseline, 14 days post-drug administration)
In the researchers’ words
This is a randomized controlled trial to explore the efficacy and safety of ND-12 combined with H-6 for patients with chronic inflammatory diarrhea
This is a short automatic summary built from the official record. A fuller plain-English card is coming; until then, please read the official record.
Questions to ask your doctor and the trial team
- Am I likely to qualify, given my health history?
- What would I have to do, and how often would I need to visit?
- Could I get a placebo? What happens to my current treatment?
- What are the possible risks and benefits?
- Are travel or other costs covered?
- What happens after the trial ends?
Official details
| Status | Recruiting |
|---|---|
| Phase | Early Phase 1 |
| Study type | Interventional |
| Conditions | Diarrhea Chronic; UC - Ulcerative Colitis |
| Lead sponsor | The Second Hospital of Nanjing Medical University |
| Collaborators | Neurodawn Pharmaceutical Co., Ltd. |
| Enrollment | 36 (estimated) |
| Start date | 2026-07-20 |
| Primary completion (est.) | 2028-08-31 |
| First posted | 2026-08-17 |
| Last updated | 2026-08-17 |
| Official title | A Randomised, Controlled, Double-blind Exploratory Study of ND-12 Combined With H-6 in the Treatment of Adult Chronic Inflammatory Diarrhea |
| ClinicalTrials.gov ID | NCT07767370 |
Interventions
- mesalazine (Drug)
Take 4 melesalazine capsules each time, 3 times a day. Continue for 14 days. - ND-12 (Drug)
Take 1 ND-12 capsule and 3 blank capsules each time, 3 times a day. Continue for 14 days - ND-12/H-6 (Drug)
Take 1 ND-12 capsule and 3 H-6 capsules each time, 3 times a day. Continue for 14 days
Full eligibility criteria (from the record)
Inclusion Criteria: 1. Subjects aged 18-75 years (inclusive), of any gender. 2. Meet any one of the following conditions: 1) Previously diagnosed ulcerative colitis, currently in the active phase; 2) Diagnosis of chronic diarrhoea: stool frequency ≥3 times per day or markedly higher than the subject's usual baseline; disease duration >4 weeks; recurrent diarrhoea with an interval of 2-4 weeks between episodes; loose stools (Bristol Stool Form Scale type 5, 6, or 7). 3\. Faecal calprotectin >150 μg/g. 4.The subject or their legal representative provides informed consent by voluntarily signing the informed consent form, fully understands the study objectives, maintains effective communication with investigators, and is capable of understanding and complying with all requirements specified in this study protocol. Exclusion Criteria: Exclusion criteria related to chronic diarrhoea 1. Presence of any of the following symptoms: 1. Fever ≥37.5°C; 2. Moderate-to-severe dehydration requiring intravenous fluid replacement; 3. Recurrent vomiting. 2. Diarrhoea caused by enteric pathogens (e.g., Clostridioides difficile, Salmonella typhi, etc.). 3. Underlying diseases that may trigger diarrhoea, including hyperthyroidism, gastrointestinal autonomic nervous dysfunction, gastrointestinal malignancy, Crohn's disease, history of colectomy (appendectomy, haemorrhoid surgery and fistula-in-ano surgery excluded), history of small-bowel resection (>20 cm of resected intestinal segment), etc. Drug-related exclusion criteria 4. Suspected drug-induced diarrhoea (e.g., long-term use of laxatives, antibiotics, chemotherapeutic agents, etc.) where discontinuation of the offending drug is not feasible. 5. History of allergy to any component of mesalazine capsules, ND-12 capsules or H-6 capsules. 6. Anticipated need for prohibited medications during the study (e.g. antibiotics, antidiarrhoeals, antiemetics, antispasmodics, etc.). 7. Use of any investigational drug within 30 days prior to enrolment into this study. Other gastrointestinal exclusion criteria 8. History of gastrectomy or vagotomy. 9. Known malabsorptive disorders include coeliac disease. 10. Known lactose intolerance. 11. Any suspected condition requiring abdominal surgery. Other exclusion criteria 12. Confirmed human immunodeficiency virus (HIV) positive status, known or suspected immunosuppression. 13. Known severe hepatic or renal insufficiency. 14. Past or current history of alcohol abuse and/or known substance abuse (cocaine, heroin, cannabis, etc.). 15. Any psychiatric condition impairing the subject's ability to understand the nature, scope and potential consequences of the study, and/or documented evidence of non-cooperation. 16. Pregnant or lactating women.
Locations (1)
| Site | City | Country | Site status |
|---|---|---|---|
| The Second Affiliated Hospital of Nanjing Medical University | Nanjing, Jiangsu | China | Recruiting |
For contacts at each site, use the official record.
Information only, not medical advice. Talk to your doctor and the trial team before making any decision about a clinical trial.